New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy

Table 1 Common adverse effects of novel agents approved for mRCC

Adverse effect	Cabozantinib N = 331		Nivolumab N = 406		Lenvatinib N = 52
Adverse effect	Any grade (%)	Grade 3/4 (%)	Any grade (%)	Grade 3/4 (%)	Any grade (%)	Grade 3/4 (%)
Diarrhea	85	11	13	1	72	12
Fatigue	65	9	35	2	50	8
Arthralgia/myalgia	11	<1	(11–21)	(0)	25	0
Decreased appetite	48	2	12	<1	58	4
Vomiting	34	2	(15–17)	(0)	39	4
Nausea	54	4	14	<1	62	8
Stomatitis	24	2	2	0	25	2
Hypertension	52	15	Not defined	Not defined	48	17
Peripheral edema	9	0	4	0	15	0
Cough	18	<1	9	0	17	2
Abdominal pain	20	4	(11–13)	(0)	31	4
Dyspnea	22	3	7	1	21	2
Decreased weight	33	2	Not defined	Not defined	48	6
Palmer-plantar erthrodysesthesia	50	8	Not defined	Not defined	15	0
Constipation	25	<1	(9–23)	(0)	37	0
Pruritus	8	0	14	0	6	0
Rash	15	<1	10	<1	17	0
	Choueiri et al. 2015 [54]		Motzer et al. 2015 [72] CheckMate 025 Trial		Motzer et al. 2015 [60, 69, 72]

Common adverse reactions observed in patients with mRCC treated with novel therapies. The incidences reported have been extracted from the clinical trials leading to each agents FDA approval, respectively. Reported incidence in parentheses were extracted from general drug data, not specific to mRCC and not from the indicated study

ISSN: 1756-8722